Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda and Indonesia partner on plasma-derived therapies
The Ministry of Health of the Republic of Indonesia (BKPM) has issued a fractionation licence to Takeda, allowing the company to collect and process plasma as part of
The Ministry of Health of the Republic of Indonesia (BKPM) has issued a fractionation licence to Takeda, allowing the company to collect and process plasma as part of
The new approvals for the anti-programmed death-1 (PD-1) therapies cover both neoadjuvant (pre-surgery) and adjuvant (post-surgery) treatment and apply to patients regardless of their eligibility for cisplatin. These
Under the deal, Teva will hold exclusive rights to commercialise both intravenous and subcutaneous formulations of the biosimilar once it obtains regulatory approval. The arrangement covers markets, including
The company signed the agreement to test the investigational therapy with Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Human Genome
AstraZeneca will obtain a licence to develop, manufacture and commercialise the phosphodiesterase 3/4 (PDE3/4) inhibitor, TQC3721, outside China. The agreement also covers certain future development programmes on an
Facilitated by Ramot, which manages technology transfer for Tel Aviv University, the agreement will combine computational and experimental tools for academic teams and scientific entrepreneurs seeking to advance
The FDA’s Office of Orphan Products Development and Office of Pediatric Therapeutics granted this status to the therapy. CMT2S is a rare, inherited neurological condition that progressively causes
Under this collaboration, Biocytogen will offer access to up to five bispecific antibodies via its RenLite platform. Whitehawk Therapeutics will assess them in conjunction with its own ADC
Approved unanimously by both companies’ boards, the acquisition will see Vertex pay $85.00 per share in cash for all outstanding shares of Crinetics. It is expected to close
The decision is based on data from the pivotal Phase III EPCORE FL-1 trial, which assessed the efficacy and safety of the fixed-duration Tepkinly plus lenalidomide and rituximab